ライフサイエンスコーパス: immunoglobulin G1

1 its humanized derivative, CAMPATH-1H (human immunoglobulin G1).

2 s fused in frame with the Fc domain of human immunoglobulin G1.

3 Gun immunizations with SERA plasmid DNA was immunoglobulin G1.

4 elia-specific antibody responses, especially immunoglobulin G1.

5 iotherapeutic filgrastim, and the Fc part of immunoglobulin G1.

6 ain of MHVR fused to the Fc portion of human immunoglobulin G1.

7 One Fab was converted to immunoglobulin G1 and analyzed for reactivity with perip

8 res priming of NK cells by immobilized human immunoglobulin G1 and costimulation through CD137L expre

9 eloped an anti-PC response consisting mainly immunoglobulin G1 and expressed the T15 heavy chain.

10 tained for all mAbs analyzed, including both immunoglobulin G1 and G2 molecules.

11 odies were found in 150 individuals (56.8%); immunoglobulin G1 and G4 were the predominant subclasses

12 ction of the Th2-associated antibody isotype immunoglobulin G1 and mediate airway inflammatory diseas

13 Antibodies to gD were exclusively immunoglobulin G1 and only neutralizing.

14 ured B cells, inducing moderate increases in immunoglobulin G1 and stronger increases in immunoglobul

15 LL clones were prepared as recombinant human immunoglobulin G1 and used as primary antibodies in enzy

16 increased serum levels of interleukin-4 and immunoglobulins G1 and E directed against hepatic triflu

17 Collision cross-sections (CCS) of immunoglobulins G1 and G4 have been determined using lin

18 Using beta2-microglobulin, immunoglobulin G1, and human growth hormone as model sys

19 An immunoglobulin G1 anti-CD47 mAb induced phagocytosis and

20 ng and a radiotracer ((99m)Tc-labeled rhesus immunoglobulin G1 anti-CD4R1 (Fab')2), we sequentially i

21 Individuals with detectable immunoglobulin G1 anti-RAMA-pr (n = 24) had fewer positi

22 DSTP3086S is a humanized immunoglobulin G1 anti-STEAP1 monoclonal antibody linked

23 Interestingly, immunoblotting with anti-immunoglobulin G1 (anti-IgG1) and anti-IgG2 specific mon

24 nd characterization of two murine monoclonal immunoglobulin G1 antibodies (MAbs), 1-F1 and 2-B12, whi

25 However, clinical trials of immunoglobulin G1 antibodies targeting this pathway reve

26 g supernatants and an increase in G-specific immunoglobulin G1 antibodies.

27 ated the antitumor activity of cetuximab, an immunoglobulin G1 antibody directed at the epidermal gro

28 node and CNS and increased antigen-specific immunoglobulin G1 antibody production.

29 Immunoglobulin G1 antibody responses were also reduced i

30 Ramucirumab is a human immunoglobulin G1 antibody that binds vascular endotheli

31 y IMC-A12, is a recombinant human monoclonal immunoglobulin G1 antibody that targets insulin-like gro

32 An Fn14-specific blocking human immunoglobulin G1 antibody variant with compromised anti

33 b, termed M1, was converted to a full-length immunoglobulin G1 antibody, M1g1, and M1g1 was produced

34 sponse, as indicated by a marked increase in immunoglobulin G1 antibody.

35 inity engineered human anti-PD-L1 monoclonal immunoglobulin-G1 antibody that inhibits the interaction

36 comparison of the F105 structure to that of immunoglobulin G1 b12, a much more potent and broadly ne

37 tial additional mechanisms, we compared four immunoglobulin G1-based (IgG1) TcE Formats (A-D) targeti

38 IA (CD16) receptor expression modulate human immunoglobulin G1 binding and antibody-dependent cell-me

39 F2 protein linked to the Fc portion of human immunoglobulin G1 (BZLF2.Fc) was expressed from mammalia

40 Antibodies of the immunoglobulin G1 class are induced in mice by T-cell-de

41 he H7 HA and either influenza virus-specific immunoglobulin G1 concentration or age.

42 (GM-CSF) or tumor necrosis factor (TNF), or immunoglobulin G1 (control), starting at 1 month of age.

43 ain Fv antibody fragments fused to the human immunoglobulin G1-derived Fc fragment under the control

44 t somatic larval antigens and changing to an immunoglobulin G1-dominated response directed at tyvelos

45 b is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody.

46 mab is a second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody that competit

47 , resulted in an affinity enhanced VHH-human immunoglobulin G1 Fc fusion molecule with subnanomolar n

48 s then recombinantly engineered with a human immunoglobulin G1 Fc region to construct the fully human

49 that is stably linked to a proprietary human immunoglobulin G1 Fc with a long half-life for preventio

50 (OBZ) is a recombinant type II anti-CD20 and immunoglobulin G1 Fc-optimized monoclonal antibody (mAb)

51 ing of a VWF-D'D3 domain fused to rFVIII via immunoglobulin-G1 Fc domains and 2 XTEN polypeptides (Am

52 trials are full-size antibodies mostly in an immunoglobulin G1 format of about 150 kDa in size.

53 antigen-specific immunoglobulin M (IgM) and immunoglobulins G1, G2, and G3.

54 kilodalton TNF receptor linked to the murine immunoglobulin G1 heavy chain.

55 The quantitative analysis of human immunoglobulin G1 (hIgG1) by mass spectrometry is common

56 rms of obinutuzumab, particularly when human immunoglobulin G1 (hIgG1) mAbs were compared.

57 A panel of immunoglobulin G1 human monoclonal antibodies (HMAbs) to

58 0) domains linked to the Fc portion of human immunoglobulin G1 (huTNFR:Fc).

59 Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting

60 ormans infection and the efficacy of passive immunoglobulin G1 (IgG1) administration were investigate

61 ENV infection induced a specific increase in immunoglobulin G1 (IgG1) afucosylation, and the levels o

62 , and 28 induced peak serum anti-HIV peptide immunoglobulin G1 (IgG1) and IgA titers of 1:131,072 and

63 nd the TH2-dependent serum concentrations of immunoglobulin G1 (IgG1) and IgE in itchy mice were also

64 in the presence and absence of anti-capsular immunoglobulin G1 (IgG1) and IgE monoclonal antibody (MA

65 In cattle, both immunoglobulin G1 (IgG1) and IgG2 can fix complement, bu

66 as the production of antigen-specific serum immunoglobulin G1 (IgG1) and IgG2a antibodies.

67 t assay-based examination of murine sera for immunoglobulin G1 (IgG1) and IgG2a immunoreactivity agai

68 sponse, where equivalent titers of anti-TTFC immunoglobulin G1 (IgG1) and IgG2a in serum were accompa

69 Serum enzyme-linked immunosorbent assays for immunoglobulin G1 (IgG1) and IgG2a revealed a predominan

70 n H. pylori-specific interleukin-12 and both immunoglobulin G1 (IgG1) and IgG2a serum titers followin

71 nd also by preincubation with purified mouse immunoglobulin G1 (IgG1) and IgG2a, but not mouse IgG3,

72 s were accompanied by impaired production of immunoglobulin G1 (IgG1) and IgG2b antibodies in respons

73 there was an increase in the level of serum immunoglobulin G1 (IgG1) and IgG2b as well as a mild inc

74 (DTH) but also high titers of WI-1-specific immunoglobulin G1 (IgG1) and IgG2b, a result indicative

75 with wild-type H. hepaticus developed serum immunoglobulin G1 (IgG1) and IgG2c responses against H.

76 al centres in the lymph node associated with immunoglobulin G1 (IgG1) and IgG3 antibody responses.

77 19F-CRM(197) alone was predominantly of the immunoglobulin G1 (IgG1) and IgM isotypes, but addition

78 Immunoglobulin G1 (IgG1) and immunoglobulin G3 (IgG3) al

79 Immunoglobulin G1 (IgG1) and immunoglobulin G3 (IgG3) an

80 icient mice produced extremely low levels of immunoglobulin G1 (IgG1) and showed increased production

81 All sera which mediate gamete lysis contain immunoglobulin G1 (IgG1) and/or IgG3 antibodies to gamet

82 m and PD-1 checkpoint immunotherapy, induces immunoglobulin G1 (IgG1) antibodies and antigen-specific

83 ated cytotoxicity (ADCC) potency than native immunoglobulin G1 (IgG1) antibodies.

84 ing to the crystal structure of a homologous immunoglobulin G1 (IgG1) antibody (PDB: 1HZH ), the back

85 Immunoglobulin G1 (IgG1) antibody predominated after the

86 th PspA-IL-2 and PspA-GM-CSF stimulated high immunoglobulin G1 (IgG1) antibody responses.

87 splay library to generate IMC-41A10, a human immunoglobulin G1 (IgG1) antibody that binds with high a

88 In that study, a humanized immunoglobulin G1 (IgG1) antibody that efficiently neutr

89 nation of the three-dimensional structure of immunoglobulin G1 (IgG1) b12 allowed modeling of the b12

90 The broadly neutralizing antibody immunoglobulin G1 (IgG1) b12 binds to a conformationally

91 The human antibody immunoglobulin G1 (IgG1) b12 neutralizes a broad range o

92 However, one such human MAb, immunoglobulin G1 (IgG1) b12, is uniquely able to neutra

93 Fab 5H2 was converted to full-length immunoglobulin G1 (IgG1) by combining it with human sequ

94 Here, we advanced the development of the C2 immunoglobulin G1 (IgG1) by humanizing it, establishing

95 Human immunoglobulin G1 (IgG1) contains 12 domains, and each h

96 nnose glycan-binding lectin Avaren and human immunoglobulin G1 (IgG1) Fc (AvFc) selectively recognize

97 protein comprised of human CD24 connected to immunoglobulin G1 (IgG1) Fc fragment.

98 termine the N-glycan type composition of the immunoglobulin G1 (IgG1) Fc fragment.

99 tumor necrosis factor alpha receptor (TNFR)-immunoglobulin G1 (IgG1) Fc fusion (TNFR:Fc) gene to the

100 imals had similar levels of antigen-specific immunoglobulin G1 (IgG1) following challenge, vaccinated

101 the genetic marker (GM) 3/17 variants in the immunoglobulin G1 (IgG1) heavy chain constant region, vi

102 FVIII) product fused with the Fc fragment of immunoglobulin G1 (IgG1) in 165 patients with severe hem

103 aracterized by high levels of virus-specific immunoglobulin G1 (IgG1) in serum and very low levels of

104 m antibody responses were biased in favor of immunoglobulin G1 (IgG1) in these mice, as there was a s

105 ve with NS3-FL were highly restricted to the immunoglobulin G1 (IgG1) isotype and were inhibited by s

106 fect being most striking for antibody of the immunoglobulin G1 (IgG1) isotype.

107 The immunoglobulin G1 (IgG1) kappa antibodies HyHEL-5 and Hy

108 SWA immunoglobulin G1 (IgG1) levels explained the effect of

109 Also, virus-specific serum immunoglobulin G1 (IgG1) levels were greatly reduced and

110 Immunoglobulin G1 (IgG1) m14 was more potent than Fab m1

111 Opsonic activities of immunoglobulin G1 (IgG1) MAbs that produce patterns term

112 ation of the disulfide bond structures of an immunoglobulin G1 (IgG1) molecule and lysozyme and by th

113 ted by cation exchange chromatography, on an immunoglobulin G1 (IgG1) monoclonal antibody (mAb).

114 Infliximab is a genetically constructed immunoglobulin G1 (IgG1) murine-human chimeric monoclona

115 genic domains of Dsg3 linked to either human immunoglobulin G1 (IgG1) or mouse IgG2a (Dsg3-Fc).

116 body levels in serum showed a dominant serum immunoglobulin G1 (IgG1) response in immunized C57BL/6 w

117 itial antibody response to L. mexicana is an immunoglobulin G1 (IgG1) response, and IgG1 preferential

118 th B7-1 and B7-2 had essentially no anti-VSV immunoglobulin G1 (IgG1) response, decreased IgG2a respo

119 ced stronger pathogen-specific Th2-dependent immunoglobulin G1 (IgG1) responses than did WT mice, and

120 e infection revealed a moderate elevation in immunoglobulin G1 (IgG1) responses, strongly enhanced Ig

121 neutralizer of infectious HeV, Fab m101, to immunoglobulin G1 (IgG1) significantly increased its cel

122 0(8) liters/mol in these studies) and of the immunoglobulin G1 (IgG1) subclass (i.e., the predominate

123 ody response consisting of predominantly the immunoglobulin G1 (IgG1) subclass and a high hemagglutin

124 nii-specific immunoglobulin primarily of the immunoglobulin G1 (IgG1) subclass with relatively little

125 icited by PsaA-Adj were predominantly of the immunoglobulin G1 (IgG1) subclass, while PsaA-IL-2 and P

126 s, we generated C8xi, a mouse/human chimeric immunoglobulin G1 (IgG1) that reacts with human but not

127 Oral F1-V mice had higher prechallenge serum immunoglobulin G1 (IgG1) titers than s.c. F1-V mice.

128 mRNA COVID-19 vaccines (n = 8) mounted lower immunoglobulin G1 (IgG1) to multiple antigenic targets i

129 By engineering the bivalent immunoglobulin G1 (IgG1) to tetra-variable domain immuno

130 Fc gamma RIIIa alter the binding affinity of immunoglobulin G1 (IgG1) to the receptor and have been a

131 ccessibility between native and afucosylated immunoglobulin G1 (IgG1) using hydroxyl radical footprin

132 ed animals given a wild-type (WT) anti-HIV-1 immunoglobulin G1 (IgG1) versus those given a Fc-Null va

133 n this report, the antiviral activity of 80R immunoglobulin G1 (IgG1), a human monoclonal antibody ag

134 Immunoglobulin G1 (IgG1), a subclass of human serum anti

135 ular domain fused to the Fc portion of human immunoglobulin G1 (IgG1), and growth factors stem cell f

136 n. immunization resulted in increased total, immunoglobulin G1 (IgG1), and IgG2a anti-HIV-1 antibody

137 which contain high levels of DTA-1-specific immunoglobulin G1 (IgG1), can induce anaphylaxis in naiv

138 ked augmentation of respiratory and systemic immunoglobulin G1 (IgG1), IgG2a, and IgA antibody levels

139 e borreliacidal activity was attributable to immunoglobulin G1 (IgG1), IgG2a, and IgG2b antibodies.

140 In a murine model of cryptococcal infection, immunoglobulin G1 (IgG1), IgG2a, and IgG2b switch varian

141 The immunoglobulin G1 (IgG1), IgG2a, and IgG2c antibody resp

142 , including the levels of RSV-specific serum immunoglobulin G1 (IgG1), IgG2a, IgA, and total IgG, and

143 ulations were found to induce high levels of immunoglobulin G1 (IgG1), IgG2b, and IgG2a antibodies al

144 Variable-region-identical mouse immunoglobulin G1 (IgG1), IgG2b, and IgG2a monoclonal an

145 tivating factor by basophils stimulated with immunoglobulin G1 (IgG1)-antigen immune complexes contri

146 ed from no effect to sharp reductions in the immunoglobulin G1 (IgG1)-to-IgG2a ratios.

147 al trials are chimeric, humanized, and human immunoglobulin G1 (IgG1).

148 munized with a mixture of vaccine and (CR2)2-immunoglobulin G1 (IgG1).

149 ed in a Th2-biased immune response with high immunoglobulin G1 (IgG1)/IgG2a antibody ratios and produ

150 tude of the antibody response as well as the immunoglobulin G1 (IgG1)/IgG2a ratio, and (iv) inclusion

151 ELISA) was used to investigate serum anti-CT immunoglobulin G1 (IgG1; long-lived response) and immuno

152 Serum anti-GD2 (immunoglobulin G1 [IgG1] and IgM) and anti-GD3 (IgG1) ti

153 Serum anti-GD2 (immunoglobulin G1 [IgG1] and IgM) and anti-GD3 (IgG1) ti

154 h ACI blood (RT1a) together with L6 (a human immunoglobulin G1 [IgG1] antibody as isotype control) or

155 recombinant urease-specific immunoglobulins (immunoglobulin G1 [IgG1] versus IgG2a) in murine sera at

156 Chimeric mAb 2C7 (human immunoglobulin G1 [IgG1]) with an E430G Fc modification

157 The MAbs PfSSP2.1 (immunoglobulin G1 [IgG1]), PfSSP2.2 (IgG2a), and PfSSP2.

158 IMCEB10 (immunoglobulin G1 [IgG1], kappa) binds with high affinit

159 nd large increases in serum antigen-specific immunoglobulin G1/immunoglobulin E using ovalbumin or As

160 ted an increased level of CVB3-binding serum immunoglobulin G1 in mice inoculated with CVB3-PL2-mIL4/

161 oliferation and interleukin-4 (IL-4)-induced immunoglobulin G1 isotype switching.

162 d inhibited efficient class switching to the immunoglobulin G1 isotype.

163 Daratumumab, a human CD38 immunoglobulin G1 kappa (IgG1kappa) monoclonal antibody,

164 (beta-lac), bovine serum albumin (BSA), and immunoglobulin G1 kappa (IgG1kappa).

165 ibritumomab tiuxetan (IDEC-Y2B8) is a murine immunoglobulin G1 kappa monoclonal antibody that covalen

166 Guselkumab is a fully human immunoglobulin G1 lambda monoclonal antibody that select

167 d with neutralizing antibody titers, anti-DV immunoglobulin G1 levels, and a multitypic 50% plaque re

168 lence of myelin oligodendrocyte glycoprotein immunoglobulin G1 (MOG-IgG) and associated clinical feat

169 envelope protein to the Fc region of a human immunoglobulin G1 molecule for use in binding assays.

170 2.6 microgram/ml) as the corresponding whole immunoglobulin G1 molecule.

171 We recently developed anti-OspA human immunoglobulin G1 monoclonal antibodies (HuMAbs) that ar

172 laque formation) was observed with two human immunoglobulin G1 monoclonal antibodies (MAbs) at concen

173 cytic activities of three PPS-specific mouse immunoglobulin G1 monoclonal antibodies (MAbs), 1E2, 5F6

174 macrophages result in variable affinity for immunoglobulin G1 monoclonal antibodies and subsequently

175 By comparison of anti-mouse P. carinii immunoglobulin G1 monoclonal antibody (MAb) 4F11(G1) and

176 We examined here whether a fully human immunoglobulin G1 monoclonal antibody (MAb) specific to

177 Emapalumab is a fully human immunoglobulin G1 monoclonal antibody directed against i

178 Ipilimumab, an immunoglobulin G1 monoclonal antibody directed against t

179 VLS-101 comprises UC-961 (a humanized immunoglobulin G1 monoclonal antibody that binds an extr

180 t with atezolizumab, an engineered humanised immunoglobulin G1 monoclonal antibody that binds selecti

181 ell transplantation (SCT) using MEDI-507, an immunoglobulin-G1 monoclonal anti-CD2 antibody.

182 S315 is a fully human, monoclonal immunoglobulin G1 neutralizing antibody, specific to the

183 fused at its C terminus to the Fc segment of immunoglobulin G1 results in markedly enhanced survival

184 B cells were expressed as mouse recombinant immunoglobulin G1 (rIgG1) monoclonal antibodies, and the

185 mice also had significantly higher anti-MoPn immunoglobulin G1 serum titers, confirming a Th2-type cy

186 -d-aspartate receptor antibodies were of the immunoglobulin G1 subclass and were able to activate com

187 ully human, recombinant monoclonal antibody (immunoglobulin G1 subclass) against insulin-like growth

188 duction and a reduction in parasite-specific immunoglobulin G1, suggesting an enhancement in Th1 resp

189 combinant p55 tumor necrosis factor receptor-immunoglobulin G1 (TNFR55-IgG1) fusion protein, decrease

190 hile platelets sensitized with a destructive immunoglobulin G1 version of the antibody (B2G1) are cle

191 PLP-specific immunoglobulin G1 was decreased in animals treated with

192 toward a decrease in serum Bet v 1-specific immunoglobulin G1 was likewise observed.

193 exploiting the stable architecture of human immunoglobulin G1 We used iterative experimental validat